Trial Profile
A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary) ; Fludarabine
- Indications Follicular lymphoma
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Takeda Oncology
- 05 Oct 2021 This trial has been completed in Spain and France (End Date: 13 Sep 2011), according to European Clinical Trials Database record.
- 27 Jun 2012 Companies added in the association field as reported by EudraCT.
- 21 Mar 2012 Planned number of patients changed from 110 to 120 as reported by European Clinical Trials Database.